Edinburgh Pathology

Dr Sarah Taylor

Post-Doctoral Researcher

Sarah Taylor
Sarah Taylor


Cancer Research UK Edinburgh Centre

Institute of Genetics and Cancer,

The University of Edinburgh,

Crewe Road South,



Current research

My research interests are focused around ovarian cancer.

I completed my PhD with Dr Simon Langdon and Prof Mark Arends, in which I worked on characterising expression changes in Fanconi anaemia proteins in high grade serous ovarian cancer, and the impact of these on chemoresistance.

I now work in the Nicola Murray Centre for Ovarian Cancer Research with Prof Charlie Gourley and Prof Simon Herrington.

My current projects involve the generation and characterisation of patient derived 3D models of ovarian cancer subtypes, and high throughput drug screening to identify novel therapies for low grade serous ovarian cancer. 


Selected Publications

Taylor SJ, Hollis RL, Gourley C, Herrington CS, Langdon SP, Arends MJ. "RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer", Front Oncol. 2024 Apr 22;14:1389472. doi: 10.3389/fonc.2024.1389472 eCollection 2024. PMID: 38711848

Taylor S, Hollis RL, Gourley C, Herrington CS, Arends MJ, Langdon SP, “RFWD3: A Potential Biomarker for Platinum Response in High Grade Serous Ovarian Cancer” (conference abstract) – Journal of Pathology April 2022; 256; pS12-S12

Taylor S, Hollis RL, Gourley C, Herrington CS, Arends MJ, Langdon SP, “Exploring the role of RFWD3 in chemosensitivity of high grade serous ovarian cancer” (conference abstract) – NCRI festival Nov 2021

Taylor S: “Curing the incurable: teaching an old drug new tricks to fight ovarian cancer”, The Observer, 17th October 2020

Taylor SJ, Arends MJ, Langdon SP, "Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer", Exploration of Targeted Anti-tumour Therapy. 2020;1:26-52, doi:10.37349/etat.2020.00003